Table 1.
Subject characteristics of patients and matched controls.
| Subject ID | Age: patient/control | Gender | Hand: patient/control | Age of Onset (yrs) | Side of TLE | HS | duration (yrs) | HIP volume ratio (I/C) patient/control |
|---|---|---|---|---|---|---|---|---|
| 2 | 49/50 | F | R/R | 30 | R | L>R | 19 | 0.97/1.08 |
| 3 | 51/54 | F | R/R | 10 | R | R | 41 | 0.71/1.01 |
| 4 | 18/18 | F | R/R | 1 | L | L | 17 | 0.82/1.01 |
| 5 | 39/38 | F | R/R | 0 | R | R | 39 | 0.82/1.02 |
| 6 | 28/27 | M | R/R | 24 | L | no* | 4 | 0.93/0.93 |
| 7 | 54/56 | F | R/R | 35 | R | no* | 19 | 0.72/1.09 |
| 8 | 18/18 | M | R/R | 12 | L | L | 6 | 0.76/0.97 |
| 9 | 43/41 | M | R/R | 33 | R | R | 10 | 0.88/0.97 |
| 10 | 24/23 | M | R/R | 1 | R | L>R | 23 | 0.59/1.00 |
| 11 | 23/23 | M | L/R | 19 | R | no* | 4 | 0.95/1.05 |
| 12 | 41/42 | F | R/R | 23 | R | R | 18 | 0.48/1.00 |
| 13 | 38/38 | F | R/R | 33 | R | R | 5 | 0.78/0.99 |
| 14 | 37/37 | F | R/R | 34 | R | R | 3 | 0.74/0.99 |
| 15 | 68/71 | M | R/R | 18 | L | L | 50 | 0.88/1.00 |
| 16 | 21/20 | M | R/L | 13 | L | L | 8 | 1.18/0.93 |
| 17 | 38/39 | F | R/L | 27 | R | R | 11 | 1.21/0.95 |
| 18 | 38/37 | M | R/R | 28 | R | R | 10 | 0.78/1.06 |
| 19 | 46/45 | F | L/R | 0 | L | L | 46 | 0.80/1.05 |
| 21 | 46/46 | M | L/R | 0 | R | R | 46 | 0.80/1.05 |
| 22 | 42/42 | F | R/L | 32 | R | no* | 10 | 1.07/0.99 |
Patients #1 and # 20 did not complete the imaging procedure and are not included in the analyses. HS = side of hippocampal sclerosis interpreted from clinical MRI; no = no sclerosis;
gliosis determined from surgical pathology; L>R = more sclerosis on left; M = male; F = female; patient and control pairs were same gender. HIP volume = hippocampal volume from FreeSurfer (ratio Ipsi/Contra).
Numbers in BOLD represent those where patient’s ratio is less than 2 standard deviations from mean of the 20 control subjects, indicating significant unilateral hippocampal volume decrease ipsilateral to focus. Matched control was ± 3 years from age of patient. Side of TLE is based on standard clinical evaluation.